loading page

SARS CoV-2 adenovirus and RNA based vaccines potential autoimmune complications: could we lower the chances?
  • Mina Kelleni
Mina Kelleni
Author Profile

Abstract

Two clinical trials of SARS CoV-2 adenovirus-based vaccines have been temporarily halted due to autoimmune complications concerns in some participants. Similarly, though the innovative SARS CoV-2 RNA based vaccines when approved to combat the current COVID-19 pandemic would be considered first of their kind, they also possess potential risks including development of autoimmune diseases. The techniques used in development of these types of vaccines should focus on the methods to decrease their potential autoimmunity. Smokers, obese and diabetic individuals are more liable groups to develop autoimmune diseases and we recommend a personalized risk benefit ratio to be evaluated before vaccination waiting for the post marketing surveillance. Further, quitting smoking, loss of overweight and control of blood glucose levels might help to lower their probabilities. Keywords: COVID-19, SARS CoV-2 adenovirus vaccine, SARS CoV-2 mRNA vaccine, autoimmune diseases. Highlights: Adenovirus and RNA based SARS CoV-2 vaccines possess a potential risk to induce auto-immune diseases RNA based SARS CoV-2 vaccines would be a first of their kind when approved to combat COVID-19 and potential autoimmune complications might be revealed only post marketing Smokers, obese and diabetic individuals are in general more liable to develop auto-immune diseases and an individualized risk benefit ratio should be considered before vaccination